Search research articles
Contact Us
Filters
Showing results (151-160 of 167) with videos related to
Page
of 17
Sort By:
Gastroenterology
|
April 21, 2009
Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer
Andrew V Biankin, James G Kench, Emily K Colvin, et al.
Nature Medicine
|
June 24, 2024
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trial
Toru Mukohara, Yeon Hee Park, David Sommerhalder, et al.
Blood
|
October 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
Meng-Xiao Luo, Tania Tan, Marie Trussart, et al.
Stem Cells (Dayton, Ohio)
|
December 24, 2016
New Monoclonal Antibodies to Defined Cell Surface Proteins on Human Pluripotent Stem Cells
Carmel M O'Brien, Hun S Chy, Qi Zhou, et al.
Plos One
|
October 23, 2010
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine
Hayley C Whitaker, Zsofia Kote-Jarai, Helen Ross-Adams, et al.
Cancer Metastasis Reviews
|
December 28, 2016
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Lacey E Dobrolecki, Susie D Airhart, Denis G Alferez, et al.
Cancer Discovery
|
December 7, 2018
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Sheau W Lok, James R Whittle, François Vaillant, et al.
Cell Death & Disease
|
March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors
Christoph Grohmann, Francesca Walker, Mark Devlin, et al.
The New England Journal of Medicine
|
August 8, 2014
Breast-cancer risk in families with mutations in PALB2
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, et al.
NPJ Breast Cancer
|
May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants
Taru A Muranen, Anna Morra, Sofia Khan, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 167) with videos related to
Sort By:
Page
of 17
Gastroenterology
|
April 21, 2009
Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer
Andrew V Biankin, James G Kench, Emily K Colvin, et al.
Nature Medicine
|
June 24, 2024
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trial
Toru Mukohara, Yeon Hee Park, David Sommerhalder, et al.
Blood
|
October 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
Meng-Xiao Luo, Tania Tan, Marie Trussart, et al.
Stem Cells (Dayton, Ohio)
|
December 24, 2016
New Monoclonal Antibodies to Defined Cell Surface Proteins on Human Pluripotent Stem Cells
Carmel M O'Brien, Hun S Chy, Qi Zhou, et al.
Plos One
|
October 23, 2010
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine
Hayley C Whitaker, Zsofia Kote-Jarai, Helen Ross-Adams, et al.
Cancer Metastasis Reviews
|
December 28, 2016
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Lacey E Dobrolecki, Susie D Airhart, Denis G Alferez, et al.
Cancer Discovery
|
December 7, 2018
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Sheau W Lok, James R Whittle, François Vaillant, et al.
Cell Death & Disease
|
March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors
Christoph Grohmann, Francesca Walker, Mark Devlin, et al.
The New England Journal of Medicine
|
August 8, 2014
Breast-cancer risk in families with mutations in PALB2
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, et al.
NPJ Breast Cancer
|
May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants
Taru A Muranen, Anna Morra, Sofia Khan, et al.
Page
of 17